Skip to main content

Advertisement

Table 1 Clinical, phenotypic and genotypic data for the linezolid-resistant Enterococci isolates investigated

From: Molecular characteristics of oxazolidinone resistance in enterococci from a multicenter study in China

Isolate no. Organism Isolation year Hospitalb Isolation site STc MICs (mg/L)a Linezolid resistance genes 23S rRNA gene mutations Other resistance genes
LNZ P AMP VAN TEC DAP TGC LVX ERY HLG Antibiotic resistance profiles
29462 E. faecalis 2009 ZRYH urine 86 8 4 <=2 2 <=0.125 0.5 0.06 8 > 4 R LVX, ERY optrA emeA, ANT(6)-Ia, AAC(6′)-Ie-APH(2″)-Ia, dfrG, dfrE, lsaA, fexA, cat, efrB, efrA, ermB, tetM, tet(L)
ZJ11066 E. faecalis 2011 ZJFY blood 116 8 2 <=2 1 0.125 0.5 0.12 8 > 4 R LVX, ERY optrA emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, dfrF, dfrG, dfrE, lnuG, lsaA, fexA, efrA, efrB, ermB, ermA1, tet(L), tetM
JS11041 E. faecium 2011 JSRM urine ND 8 > = 64 > = 32 0.5 0.25 2 0.06 8 > 4 R P, AMP, LVX, ERY ND
19113 E. faecalis 2011 SZRM bile ND 8 > = 64 > = 32 2 <=0.125 0.5 0.06 1 > 4 R P, AMP, LVX, ERY ND
ZJLRE1 E. faecium 2011 ZJFE blood ND 16 > = 64 > = 32 1 0.5 1 0.06 8 > 4 R P, AMP, LVX, ERY G2658 T ND
1207_26W003 E. faecalis 2012 BJRM urine 476 4 2 <=2 1 0.12 0.5 0.06 8 > 4 R LVX, ERY optrA emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, aad(6), ANT(9)-Ia, dfrG, dfrE, lnuB, lsaE, lsaA, mdtF, SAT-4, cat, fexA, efrB, efrA, ermA1, ermB, tet(L), tetM
1203_10W003 E. faecalis 2012 BJRM urine 480 8 2 <=2 1 0.12 0.5 0.06 8 > 4 R LVX, ERY optrA emeA, AAC(6′)-Ie-APH(2″)-Ia, APH(3′)-IIIa, aad(6), ANT(6)-Ia, dfrG, dfrE, lnuB, lsaE, lsaA, SAT-4, cat, fexA, efrA, efrB, ermB, ermA1, tetM, tet(L)
19677 E. faecalis 2012 SZRM blood 59 8 2 <=2 0.5 0.12 0.5 0.12 0.03 > 4 R ERY optrA emeA, dfrE, lsaA, fexA, efrA, efrB, ermA1, tetM, tet(L)
19506 E. faecium 2012 SZRM wound 18 16 > = 64 > = 32 0.5 0.25 2 0.06 8 > 4 S P, AMP, LVX, ERY optrA AAC(6′)-Ii, dfrG, efmA, msrC, fexA, ermA1
1202_13E004 E. faecalis 2012 BJRM wound 416 16 8 <=2 2 <=0.125 0.5 0.12 8 > 4 R LVX, ERY optrA emeA, ANT(6)-Ia, AAC(6′)-Ie-APH(2″)-Ia, dfrG, dfrE, lsaA, fexA, efrB, efrA, ermB, ermA1, tet(L), tetM
1202_21W014 E. faecalis 2012 BJRM urine 21 8 4 <=2 2 <=0.125 0.5 0.12 8 > 4 R LVX, ERY optrA emeA, AAC(6′)-Ie-APH(2″)-Ia, aad(6), ANT(6)-Ia, dfrG, dfrE, lnuG, lsaA, SAT-4, fexA, cat, efrA, efrB, ermB, tet(L)
SZ21494 E. faecalis 2012 SZRM wound 67 8 4 <=2 1 <=0.125 1 0.06 1 > 4 S ERY optrA emeA, dfrE, dfrG, lnuG, lsaA, fexA, cat, efrA, efrB, ermB, ermA1, tetM, tet(L)
XM2013_71028 E. faecalis 2013 XMDY wound 16 8 2 <=2 1 <=0.125 1 0.06 0.5 > 4 R ERY optrA emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, ANT(9)-Ia, aad(6), dfrG, dfrE, lnuB, lsaE, lsaA, SAT-4, fexA, cat, efrB, efrA, ermB, ermA1, tetM
XM2013_42321 E. faecalis 2013 XMDY urine 585 16 4 <=2 1 <=0.125 0.5 0.06 8 > 4 R LVX, ERY optrA emeA, APH(3′)-IIIa, AAC(6′)-Ie-APH(2″)-Ia, aad(6), ANT(9)-Ia, dfrE, dfrG, lmrD, lnuB, lsaE, lsaA, SAT-4, cat, fexA, efrB, efrA, ermB, tetM, tet(L)
TZ2 E. faecalis 2013 TZSY blood 476 8 2 <=2 1 <=0.125 0.5 0.12 8 > 4 R LVX, ERY optrA emeA, AAC(6′)-Ie-APH(2″)-Ia, APH(3′)-IIIa, aad(6), ANT(6)-Ia, dfrG, dfrE, lsaA, SAT-4, fexA, cat, efrB, efrA, ermA1, ermB, tet(L), tetM
WHXH E. faecalis 2013 WHDS blood 476 8 4 <=2 2 <=0.125 0.5 0.12 8 > 4 S LVX, ERY optrA emeA, AAC(6′)-Ie-APH(2″)-Ia, APH(3′)-IIIa, aad(6), ANT(9)-Ia, dfrE, dfrG, lnuB, lsaE, lsaA, SAT-4, cat, fexA, efrB, efrA, ermB, tetM, tet(C), tet(L)
  1. aMICs, the minimal inhibitory concentrations; LNZ, linezolid, susceptible (S): ≤ 2 mg/L, intermediate (I): 4 mg/L, resistant (R): ≥ 8 mg/L; P, penicillin, S: ≤ 2 mg/L, R: ≥ 8 mg/L; AMP, ampicillin, S: ≤ 2 mg/L, R: ≥ 8 mg/L; VAN, vancomycin, S: ≤ 4 mg/L, I: 8–16 mg/L, R: ≥ 32 mg/L; TEC, teicoplanin, S: ≤ 8 mg/L, I: 16 mg/L, R: ≥ 32 mg/L; DAP, S: ≤ 1 mg/L, susceptible-dose dependent (SDD): 2–4 mg/L, R: ≥ 8 mg/L; TGC, tigecycline, no breakpoint in CLSI M100; LVX, levofloxacin, S: ≤ 2 mg/L, I: 4 mg/L, R: ≥ 8 mg/L; ERY, erythromycin, S: ≤ 0.5 mg/L, I: 1–4 mg/L, R: ≥ 8 mg/L; HLG, high-level gentamycin (500 mg/L); −, negative; ND, not determined
  2. bZRYH, China-Japan Friendship Hospital; ZJFY, 1st Affiliated Hospital of Zhejiang University; JSRM, Jiangsu Province Hospital; SZRM, Shenzhen People’s Hospital; ZJFE, 2nd Affiliated Hospital of Zhejiang University; BJRM, Peking University People’s Hospital; XMDY, 1st Affiliated Hospital of Xiamen University; TZSY, Taizhou Hospital of Zhejiang Province; WHDS, Wuhan Fourth Hospital
  3. cST sequence type, ND not determined